Documented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollment\r\n* NOTE: If patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST)
Patients must have newly diagnosed, stage IIA – IV disease and must be entered within eight weeks from surgery; they may have either measurable residual disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, or they may have no measurable residual disease; OR, they must have biopsy-proven recurrent disease of any stage and have never received cytotoxic chemotherapy
Disease must be measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; disease that has undergone local therapy in the past 30 days is not considered measurable unless the investigator has documented progression despite the local therapy (for treatment phase)
Metastatic or unresectable disease and at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria; NOTE: Nephrectomy or ablation of the primary tumor is allowed prior to enrollment
Dose expansion phase only: must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 (those undergoing pre-treatment resection must have imaging assessment after resection to determine measurability)\r\n* Previously irradiated sites of tumor may be considered measurable if there is radiographic progression at that site subsequent to the time of completing radiation
At least 1 measurable target lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Participants enrolled in the Phase I portion must have evaluable disease; participants enrolled in the Phase II portion must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have evidence of radiographic disease progression within the past 12 months; progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria is not required
Has measureable disease by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) 1.1 criteria.
Dose expansion only: Subjects must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria; this lesion must be outside a previously irradiated area
For Part 1: Participant must have evaluable disease. For Part 2: Participant must have measurable disease according to Response Criteria in Solid Tumors (RECIST) v1.1
Must have at least one measurable lesion per irRECIST (immune-related Response Evaluation Criteria Criteria in Solid Tumors):
Evaluable disease, either measurable on physical examination or imaging by Response Evaluation Criteria in Solid Tumors (RECIST v1.1, Appendix 2), or by informative tumor marker(s).
For Parts A, B, C, D, E, and F: Have either measureable disease or nonmeasureable but evaluable bone disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
At least 1 measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) meeting the following criteria:
At least one target lesion based on the evaluation criteria in solid tumors (RECIST 1.1).
Participants must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; bone lesions are not considered measurable by definition
Has ?1 distant and/or discrete non-injected lesion that is amenable to biopsy via visual inspection or amenable to biopsy via image guidance, such as ultrasound or computed tomography/magnetic resonance imaging (CT/MRI). This lesion must be measurable as defined by the response criteria used to assess the participant (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] for solid tumors or revised International Working Group [IWG] criteria for lymphomas).
Dose escalation cohorts of FAZ053 single agent and FAZ053 in combination with PDR001: Patients with advanced/metastatic solid tumors with measurable or non-measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 who may or may not have received prior treatment with an immune checkpoint inhibitor, who have progressed despite standard therapy, or for whom no standard therapy is available.
Assessable disease status defined by Cheson (for lymphoma) or modified severity weighted assessment tool (mSWAT) (for mycosis fungoides [MF] and Sezary syndrome [SS]) criteria, or having measurable tumors defined by Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1) (for solid tumor)
Part A (all cohorts): Have the presence of measureable and /or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
The patient must have disease that is measurable by standard imaging techniques, per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), or evaluable per RECIST 1.1. (For patients with prior radiation therapy, measurable lesions must be outside of any prior radiation field[s], unless disease progression has been documented at that disease site subsequent to radiation.)
Tumor size is measurable - measurable tumor criteria will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable metastatic melanoma with at least one lesion that is resectable for TIL generation and at least one other lesion that can be measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have MBC that is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Patients with metastases limited to the bones are eligible.
Patients must have measurable disease, documented according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, or evaluable disease with a standard tumor marker (alpha-fetoprotein [AFP] and/or human chorionic gonadotropin [HCG]) greater than 10 times the upper limit of normal
Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; for example, this would include tumor in the lung, liver, and retroperitoneum; bone disease is difficult to follow and quantify and as a sole site would not be acceptable
Patients may have disease that is measurable or non-measurable but evaluable disease (e.g. present on bone scan, rising tumor markers, non-measurable by Response Evaluation Criteria in Solid Tumors [RECIST] but visible on computed tomography [CT] scan); patients with third space fluid (for example pleural effusions) as only site of disease will not be eligible
Measurable metastatic (stage IV) gastric, gastroesophageal, pancreatic, hepatocellular carcinoma, cholangiocarcinoma, gallbladder, colorectal, urothelial, breast, ovarian/endometrial carcinoma, or glioblastoma  with at least one lesion that is resectable for TIL generation with minimal morbidity preferentially using minimal invasive laparoscopic or thoracoscopic surgery for removal of superficial tumor deposit, plus one other lesion that can be measured by Response Evaluation Criteria In Solid Tumors (RECIST) criteria
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) and obtained by imaging within 30 days prior to being registered for protocol therapy
Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, including at least one tumor lesion that meets criteria for multi-organ site ablative radiation therapy (MOSART) SBRT radiation\r\n* 0.25 cc to 65 cc of viable tumor (i.e. primary disease of metastases) approximately 5 cm in maximal dimension; tumors larger than 65 cc can be partially treated\r\n* Metastases located in lung, liver, mediastinal/cervical node, spinal/paraspinal, osseous, abdominal-pelvic (lymph node/adrenal gland)
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; radiographic tumor assessment performed within 28 days before treatment; target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site after the completion of radiation therapy
The participant has the presence of measurable and/or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST Version 1.1). Response Assessment in Neuro-Oncology (RANO) Criteria or Macdonald Criteria should be used for CNS tumors.
Subjects must have received neoadjuvant chemotherapy (any number of cycles) with complete or partial response as assessed by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)
Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)1.1 or pure lytic or mixed lytic-blastic bone lesions
Metastatic disease of at least two non-central nervous system (CNS) sites (including the index lesion to be treated) measurable by RECIST criteria with at least one site outside of the radiation field and evaluable by RECIST criteria for evaluation of response
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; patients without measurable disease may be included on study after discussion with the sponsor, given that the primary endpoint of the study is Ki-67 of TIL (flow cytometry)
In dose expansion, at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 which can be followed by CT or magnetic resonance imaging (MRI)
Subjects must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Radiographic tumor assessment performed within 28 days of study inclusion.
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and be able to be followed over time by Immune related response criteria (irRC) for treatment decisions
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 including at least two metastatic lesions that meet criteria for SBRT radiation\r\n* 0.25 cc to 65 cc of viable tumor (i.e. primary disease or metastases) approximately 5 cm in maximal dimension; tumors larger than 65 cc can be partially treated
The subject has a biopsy-proven diagnosis of adenocarcinoma of the pancreas (or recurrence of previously resected disease) with metastatic disease that is measurable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Must have measurable disease by radiographic or physical criteria suitable for evaluation according to RECIST v1.1 for documentation of disease response or progression.
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Metastatic disease that is evaluable radiologically by Response Evaluation Criteria in Solid Tumors (RECIST) or MD Anderson criteria, which will allow for bone-only disease
Documented disease recurrence/progression based on Gynecologic Cancer Intergroup (GCIG)-Response Evaluation Criteria in Solid Tumors (RECIST)
Patients with the presence of at least one measurable lesion as defined by RECIST 1.1 criteria for response assessment
Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria independent of the lesion irradiated
Have measurable disease with at least 1 unidimensional lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
For patients enrolled in arm A dose level 4, arm A 14-patients expansion cohort, and arm B (first stage of phase II of TRC102 and pemetrexed) measurable disease is required according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural mesothelioma; pleural effusion and ascites are not considered measurable disease
Progressive disease based on radiological imaging within 12 months; Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 would be used to assess measurable disease burden
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria that has not been previously irradiated and which can be followed by computed tomography (CT) or magnetic resonance imaging (MRI)
Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; baseline measurements and evaluations must be obtained within < 4 weeks of enrollment; disease in previously irradiated sites is considered measurable if there has been unequivocal disease progression or biopsy-proven residual carcinoma following radiation therapy
All patients must have measurable lesions according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 must have at least 1 tumour lesion amenable to biopsy, and must be medically fit and willing to undergo a biopsy before first treatment and, unless clinically contraindicated, after 6 weeks on therapy
Patients with metastasis outside of the abdominal cavity; except\r\n* Disease outside of the abdomen that is non-measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria will be allowed
At least one clinically evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
All patients must have evaluable disease as defined as:\r\n* Solid tumors must have a lesion evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1\r\n* Central nervous system tumors will be evaluated by Response Assessment in Neuro-Oncology (RANO) criteria\r\n* Leukemia patients must have > 10% blasts (or blast equivalent) in the bone marrow
At least one site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) scan done within 30 days prior to study start
Have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) and have at least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; the target lesion(s) should also have bi-dimensional measurability for RECIST 1.1 evaluation on study
Subjects, including those in the dose-escalation portion of the study, must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; imagining must be within 28 days of trial enrollment\r\n* Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site prior to trial enrollment
Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST); the measurable lesion(s) must be outside the field of radiation therapy (RT) if there was prior treatment with RT unless progression at the site has occurred
Have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); NOTE: Enrollment of patients with bone-only disease may be limited if we find we are not able to get adequate tissue for research correlates from bone biopsies
INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients must have measurable disease by at least one of the criteria below:\r\n* Extra skeletal disease that can be accurately measured in at least one dimension as >= 10 mm with conventional computed tomography (CT) techniques as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\r\n* Skeletal or bone-only disease measurable by fludeoxyglucose F 18 (FDG) positron emission tomography (PET) imaging
Measurable or evaluable indicator lesion(s) as defined by RECIST v1.1; patients without RECIST measurable disease will be eligible for enrollment to \Other\ cohort provided their disease can be evaluated using another accepted response criteria (e.g. Gynecologic Cancer InterGroup [GCIG] CA125 response criteria, positron emission tomography [PET] Response Criteria in Solid Tumors [PERCIST])
Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 including at least two tumor lesions that meet criteria for multi-organ site ablative radiation therapy (MOSART) SBRT radiation\r\n* 0.25 cc to 65 cc of viable tumor (i.e. primary disease or metastases) approximately 5 cm in maximal dimension; tumors larger than 65 cc can be partially treated\r\n* Metastases located in lung, liver, mediastinal/cervical node, spinal/paraspinal, osseous, abdominal-pelvic (lymph node/adrenal gland)
Patient has measurable disease by RECIST version 1.1 (solid tumors) or Lugano (lymphoma) criteria or evaluable or measureable disease by Macdonald criteria (rHGG).
At least one Response Evaluation Criteria in Solid Tumors (RECIST)-defined target lesion; patient must have documented disease progression
Measurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; tumor lesions previously irradiated or subjected to other loco-regional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documented
Patients with any type of malignancies; and/or HIV/AIDs; and/or history of solid organ transplant; and/or Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have evidence of metastatic disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease; Note: measurable lesions include lytic or mixed (lytic + blastic) bone lesions, with an identifiable 10 mm soft tissue component that meets the measurability criteria per RECIST
Medically unresectable (stage I-II) or locally advanced (stage III); patients with distant metastases (stage IV) must have stable disease or improved disease (partial response, or complete response) per Response Evaluation Criteria in Solid Tumors (RECIST) criteria as determined on serial imaging following a course of chemotherapy
Patients must have evaluable disease – defined as one of the following:\r\n* Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease OR\r\n* Evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related) AND a cancer antigen 125 (CA125) that has doubled from the post-treatment nadir and is also greater than 2 times upper limit of normal (ULN)
Has clinical response or stable disease for minimum of two months (three cycles of every three week chemotherapy or 8 weeks of weekly regimen, etc.) after receiving any prior chemotherapy for metastatic/recurrent disease; a minimum of two cycles (6-8 weeks) of chemotherapy is required to determine clinical response; per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, clinical response for measurable disease is defined as complete response (CR) or partial response (PR); for non-measurable disease only (i.e. bone metastasis, ascites, pleural effusion, and pathological lymph nodes >= 10 to < 15 mm short axis) is defined as persistence of one or more non-target lesion(s) and no increase in overall tumor burden
Disease progression based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria while the subject has been taking fulvestrant, and for which continuation of endocrine therapy would be appropriate
Histological diagnosis of ameloblastoma; all stages are eligible; patients must have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Progressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator within the 12 months preceding study enrollment
All patients must have measurable or evaluable disease defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; if the patient has received prior radiation therapy one measurable lesion must be outside the irradiated field; lesions within an irradiated field will be followed as non-target lesions and considered evaluable; if the only site of measurable disease is within a previously irradiated field then 6 months must have elapsed between the completion of radiation therapy and entry on study to be considered measurable; if the specific diagnosis occurs radiologically as standard of care and a diagnostic procedure is too dangerous for any reason, subjects may be enrolled on study based on the presumptive radiographic diagnosis
At least one measurable lesion as assessed by computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable metastatic disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria,\r\n* Must be amenable to ultrasound or computed tomography (CT)-guided biopsy of one metastatic lesion\r\n* Peritoneal disease as the sole site of occult metastasis or presenting as malignant ascites is acceptable if a cell block of tumor cells can be obtained showing > 20% viable tumor cells
Patients must have one target lesion to be utilized in order to assess response per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version (v)1.1\r\n* Lesions that have previously been treated with stereotactic radiosurgery (SRS) are excluded as measurable disease because distinction of radiation necrosis and tumor progression can be difficult in this setting and enlargement of the lesion may not necessarily mean progression
The target lesion(s) can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST)
The subject has a histologic or cytologic diagnosis of a DTC tumor (including poorly differentiated thyroid cancer but not anaplastic thyroid cancer) that is metastatic or unresectable and fulfills the following criteria:\r\n* Subjects must have progressive disease as defined by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria when comparing baseline scans to those obtained within the prior 14 months AND\r\n* Subject must have radioiodine (RAI)-refractory disease based on at least one of the following:\r\n** Prior dose of RAI exceeding 600mCi\r\n** Progression of disease within 18 months following a dose of >= 100mCi\r\n** Presence of target lesions as defined by modified RECIST criteria which do not take up RAI
Patients are not required to have measurable disease by traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria, as lesions in the pancreas are notoriously hard to measure radiographically; however, patients must have disease which is evaluable for resection
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; at least one measurable lesion needs to be outside the field of prior therapeutic radiation or has progressed after radiation
Measurable tumor according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with at least one unidimensionally measurable target lesion
Histologically proven pancreatic adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on imaging as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (or for thymic carcinoma, at least one measurable lesion per International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 criteria
Radiographic evidence of metastatic disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria OR by prostate cancer-specific positron emission tomography (PET) imaging; evaluable non-target lesions and/or bone only metastasis are permitted per RECIST 1.1 and Prostate Cancer Clinical Trials Working Group (PCWG3) guidelines; non-target, pathological lymph nodes >= 10 mm and less than 15 mm in the short axis are permitted
The target lesion(s) can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST) and must have a maximum tumor volume of =< 100 cm^3
Stage II of the trial: evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria must be present for all subjects in the randomized component of the trial– if surgery or radiation is planned, the target lesions may not be so treated until after the assessment of the effect of chemotherapy
Patients with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria by imaging techniques are not eligible to proceed to the second transplant; tumor marker increase alone is not sufficient to diagnose disease progression
Documented progression of disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as any progression that requires a change in treatment, prior to randomization
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the site study team. Target tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions;
At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) in contrast enhanced (unless contraindicated) CT or MRI
Subject has measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; tumor lesions situated in previously irradiated areas are considered measurable if progression has been demonstrated in such lesions
At least one evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1criteria; (patients whose only nodal disease is cystic and not positron emission tomography [PET]-avid are not eligible)
At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in contrast enhanced (unless contraindicated) CT or MRI.
RENAL COHORT: Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria in at least one site that is not the site for planned surgical resection or serial biopsy
Phase II only: Must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Metastatic disease in at least two distinct lesions (including the index lesion to be treated) with at least one site outside of the radiation field and evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for evaluation of response
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or at least one site of disease must be uni-dimensionally measurable as per RECIST 1.1. All radiology studies must be performed within 28 days prior to registration
Histologically proven metastatic pancreatic or colorectal adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Bi-dimensionally measurable disease by radiographic imaging (computed tomography [CT] scan) that represents at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and obtained by imaging within 28 days prior to registration for protocol therapy; disease in an irradiated field as the only site of measurable disease is acceptable only if there has been clear progression since completion of radiation treatment
Patients must have a clinically measurable primary oropharyngeal tumor, defined as measuring >= 1 cm by spiral computed tomography (CT), per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, and/or by clinical examination
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1 and >= 1 site safe for biopsy
Subjects who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 or elevated tumor markers (human chorionic gonadotropin [hCG], alpha-fetoprotein [AFP])\r\n* Note: patients without measurable disease are allowed on the study as long as they have clearly rising tumor markers and they will be exempt from biopsy
ARM A: Histologically or cytologically confirmed hepatocellular carcinoma that is refractory (by Response Evaluation Criteria in Solid Tumors [RECIST] or modified [m]RECIST criteria or with unequivocal clinical progression of disease) to or intolerant (defined as inability to administer further sorafenib due to drug related toxicities) of sorafenib based therapy or advanced solid tumor with liver predominant disease burden that has progressed on or is intolerant to standard
Subjects with extracranial disease must have evaluable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); subjects affected by glioma must have evaluable disease by Response Assessment in Neuro-Oncology Criteria (RANO) criteria
Patients with confirmed diagnosis of ECD that are asymptomatic and with no visceral involvement are not eligible for this trial (patients with no target lesions as per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria)
Must have a minimum of 3 radiographically distinct (> 1.5 cm) lesions measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at time of study enrollment (> 5 preferred)\r\n* A maximum of 2 metastases per treated organ may be targeted for HD-XRT, but must be separated by more than 5 cm of normal tissue\r\n* At least 2 non-irradiated lesions are required for systemic response assessments
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or evaluable cancer via cancer antigen (CA)125 Gynecologic Cancer Intergroup (GCIG) criteria
Patients enrolled in the dose expansion phase must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumors or measurable nodal disease at baseline as defined by Cheson criteria for lymphoma
Measurable or evaluable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for non-GBM tumors and by Response Assessment in Neuro-Oncology (RANO) criteria for GBM
Evaluable disease, as follows:\r\n* For phase IA dose escalation: have the presence of any evaluable disease, including bone metastases, effusion, or cystic metastases\r\n* For phase IB extension only: have progressive and measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v 1.1)
Patients must have measurable or non-measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to registration (Phase I)
Non-measurable and/or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, or abnormal cancer antigen (CA)-125 to levels (in patients with ovarian cancer) at least 1.5 x normal documented by two independent measurements at least 4 weeks apart
Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria; X-rays, scans or physical examinations used for tumor measurement must have been completed within 28 days prior to registration; X-rays, scans or other tests for assessment of non-measurable disease must have been performed within 42 days prior to registration
Has at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as confirmed by the blinded central imaging vendor.
At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for response assessment (certain exceptions may apply)
Measurable or non-measurable (but radiologically evaluable) disease per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 on computed tomography (CT) scan (within 28 days of randomization) with at least one lesion outside previously irradiated areas.
Patients in the phase II portion must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; previously irradiated sites can be included if there is documented progression of disease in that site; patients in the phase I portion do not require measurable disease by RECIST 1.1 criteria
At least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
Participant must have at least 1 unidimensional measurable NSCLC lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1).
As defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the Revised Response Criteria for Malignant Lymphoma or the Response Assessment in Neuro Oncology (RANO) criteria for glioblastoma:
Have at least one untreated and progressing tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumor
Must have measurable tumor per Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST for malignant pleural mesothelioma
Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens including but not limited to cancer antigen (CA-125) and prostate-specific antigen (PSA).
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation; the pleural mesothelioma cohort will require measurable disease according to modified RECIST
Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as confirmed by the blinded central imaging vendor
Has measurable disease at baseline based on Response Evaluation Criteria is Solid Tumors (RECIST) 1.1 as determined by the central imaging vendor
Measurable disease as defined by Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST).
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) (Response Evaluation Criteria in Solid Tumors [RECIST] criteria 1.1)
Have either measureable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Measurable disease according to modified RECIST (Response Evaluation Criteria In Solid Tumours) criteria
Patients with at least one measurable skin metastases and distant, measurable metastases (outside of skin) by Response Evaluation Criteria in Solid Tumors (RECIST); for patients without distant measurable metastases, an area of the skin metastases designated to not receive local therapy can be substituted; patients with multiple (>= 2) metastatic sites (skin involvement not required), with at least one site measurable by RECIST, will be eligible for the CTX/RT cohort
At least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
The patient must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and must have one site amenable to biopsy that, in the opinion of the investigator and/or interventional radiologist, is likely to yield acceptable tumor sample for a core biopsy per the above pathology criteria
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria or any other baseline prerequisite for the assessment of the principal judgement criteria
Have a diagnosis of NSCLC with at least 1 measurable lesion assessable using standard techniques by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
Presence of measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1, Eisenhauer et al. 2009).
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by computed tomography (CT) scan, or for skin lesions not measurable by CT scan, measurements may be performed with caliper or flexible ruler\r\n* Note: stage IV no evidence of disease (NED) is excluded by this criterion
Patients should have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; if no measurable disease is present, patients should have assessable disease such as pleural effusion, ascites, with cancer antigen 125 (CA125) Gynecological Cancer Intergroup (GCIG) criteria
Measurable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; a lesion in a previously irradiated area is ineligible to be considered as measurable disease unless there is objective evidence of progression of the lesion prior to study enrollment
Subject must have at least 1 unidimensional measurable NSCLC lesion on a Computerized Tomography (CT) scan as defined by Response Evaluation Criteria In Solid Tumors (RECIST - version 1.1).
Measurable disease by Computed tomography (CT) or Magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria
Measurable (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) indicator lesion not previously irradiated
At least one measurable metastatic lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria; ascites, pleural effusions, and bone metastases are not considered measurable; minimum indicator lesion size = 10 mm by helical computed tomography (CT) or = 20 mm by conventional techniques; pathological nodes must be = 15 mm by the short axis to be considered measurable
No disease progression (i.e. stable disease [SD] or better response by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) at the completion of chemotherapy.
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, which includes locoregional lesions (not amenable to curative surgery and/or radiation) and distant metastatic lesions
Patients must have at least one tumor lesion that meets the following criteria: the lesion can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumor (RECIST)
Measurable tumor according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with at least one unidimensionally measurable target lesion
One or more measurable metastatic tumors measurable on CT san per Response Evaluation Criteria in Solid Tumors (RECIST v.1.1 ), excluding the primary lesion.
Evidence of metastatic disease with measurable lesion(s) as defined by RECIST guideline version 1.1 to permit tumor response evaluation; subjects with unresected primary tumors may be enrolled as long as evidence of measurable metastatic disease is also present
Patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to randomization and must be acquired by multiphasic CT or contrast magnetic resonance imaging (MRI)
Progressive disease after androgen deprivation, as defined by Prostate Cancer Working Group 2 and/or Response Evaluation Criteria in Solid Tumors criteria
Patients must have at least one site of measurable disease (if applicable) (per RECIST for solid tumors or the appropriate disease classification/criteria for the target population)
Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
At least one clinically evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have a primary or metastatic lesion measurable in at least one dimension by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1 within 4 weeks prior to entry of study
Measurable disease by Response Evaluation Criteria in Solid Tumors- (RECIST) 1.1 criteria; previous irradiated tumor is acceptable if there is at least a 20% increase in the size of the previously irradiated lesion
In continuous complete or partial remission or stable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) after standard first-line treatment.
As defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or the Revised Response Criteria for Malignant Lymphoma
Patient on the dose-escalation portion of the trial must have evaluable disease, defined as either measurable (by Response Evaluation Criteria in Solid Tumors [RECIST]) or non-measurable disease (e.g. bone mets, pleural effusion or lymphangitic spread); measureable disease is required for patients in the expanded RP2D cohort
Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). A lesion that has been previously treated by local therapy will qualify as a measurable or evaluable lesion if there was demonstrable progression following locoregional therapy
Patients may be registered on study prior to completing all chemotherapy but only those having a response or stable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria after 3 to 6 cycles of first-line chemotherapy may proceed on study with SBRT/radiation therapy (RT) treatment
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 besides the tumor that is expected to be radiated; bony lesions without soft tissue component are not measurable lesions
Patient has at least one measurable nodal lesion (>= 2 cm) according to Response Evaluation Criteria in Lymphoma (RECIL) criteria
Measurable and/or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and/or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria; bone only disease is allowed
Patient must have at least 1 site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) or magnetic resonance imaging (MRI) which will not be irradiated
At least 1 measurable target lesion according to Response Evaluation in Solid Tumors (RECIST) 1.1
Measurable (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) indicator lesion not previously irradiated
Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with progressing or new tumors since last antitumor therapy
Have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
Have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CRPC participants may be enrolled with objective evidence of disease as per Prostate Cancer Working Group (PCWG2) criteria
Measurable indicator lesion by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Subject has at least 1 measureable lesion (not including any lesion that was irradiated) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
At least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have at least one uni-dimensional measurable lesion by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST)version 1.1. (applicable only in Phase 2)
At least 1 solid tumor lesion measurable by computer tomography (CT) scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Disease progression by PSA criteria (PSA Working Group Consensus Criteria Eligibility) and/or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)-1.1 criteria; previous irradiated tumor is acceptable if there is at least a 20% increase in the size of the previously irradiated lesion
Patients must have evaluable disease; measurable disease is not required; however, if measurable disease is present, it is defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1; furthermore, if only evaluable disease is present, a relevant tumor marker (per investigator discretion) must be >= 2 times upper limit of normal (ULN) at baseline, and can be used as a response indicator
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
Have at least 1 extracranial metastasis that is amenable to radiation and at least 1 other site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Subjects must have at least two lesions:\r\n* At least one lesion must be safely amenable to irradiation and likely to meet criteria delineated in the judgement of the treating radiation oncologist; this can be a lesion that was previously irradiated as long as prior radiation was at least 6 months prior to projected first fraction of SBRT and as long as reirradiation dose constraints as outlined are being met\r\n* A separate, not-to-be-irradiated lesion measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria
Patient’s disease must be bi-dimensionally measurable by caliper or radiological method as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) criteria; for subjects with a single lesion, archived tissue must be available for research analysis; multiple superficial melanoma lesions must have an aggregate total diameter of >=10 mm
Have at least 1 measurable lesion outside of the central nervous system (CNS) whose presence is assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Histologically proven pancreatic adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patient must have previously progressed on abiraterone (either by PCWG2 criteria or Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
Radiographically documented measurable disease at study entry per response evaluation criteria in solid tumours ( RECIST) v1.1.
Measurable (Response Evaluation Criteria In Solid Tumors [RECIST 1.1]) indicator lesion not previously irradiated
At least one target lesion that has not been treated with local therapy and is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Previously treated with trametinib on Arm A and experienced objective disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have achieved a complete response (CR) or partial response (PR), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, following treatment for recurrent ovarian, fallopian tube, or peritoneal cancer; histological confirmation of the original primary tumor is required
Stage IV disease as evidenced by soft tissue, visceral and/or bony metastasis must be Response Evaluation Criteria in Solid Tumors (RECIST) evaluable on computed tomography (CT) scan and/or bone scan
Radiographically measurable disease; measurable disease is defined as disease that can be assessed with 2-dimensional measurements on a cross-sectional imaging; minimum lesion size is 2 cm in greatest diameter as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Subjects with advanced and/or metastatic solid tumors or B-NHL who are either refractory to or have relapsed from standard therapies, or for whom a standard therapy does not exist with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Documented progressive disease based on investigator assessment according to Response Evaluation Criteria in Solid Tumours (RECIST) following receipt of at least two cycles of cisplatin or carboplatin administered for R/M disease
Patients enrolled in the dose expansion phase must have at least one measurable lesion as defined by RECIST criteria for solid tumors or Measurable nodal disease at baseline as defined by Cheson criteria for Lymphoma.
Patients must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria that has not been previously irradiated; if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation
The participant must have a tumor measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, measurable by elevated tumor markers (eg, 24-hour urine 5-HIAA, chromogranin A, adrenocorticotropin hormone (ACTH), gastrin, or other tumor specific biochemical markers), or both
Patients must have measurable disease either primary and/or metastatic masses reproducibly measurable in one or two diameters by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 parameters by CT scan or MRI scan; positron emission tomography (PET) or octreotide scans are useful adjuncts but will not be used to measure response
Documented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollment; NOTE: if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; at least one measurable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST)
Cutaneous tumor deposits that, in the opinion of the investigator are amenable to sequential biopsies for correlative analyses; in addition to these, all patients must have measurable disease (i.e., present with at least one measurable lesion per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1)
Symptoms uncontrolled by somatostatin analogues OR morphologically progressive tumor by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in the liver OR baseline tumor burden > 25% of the liver volume
Have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and/or Prostate Cancer Working Group 2 (PCWG2) criteria
Patients must have measurable or evaluable/non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; patients with bone only disease are not eligible; NOTE: for patients with metastatic disease in the liver, tumor burden should not be deemed significant (e.g., to no more than 30% of total liver volume as assessed by local review/investigator)
Patients must have either measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) or evaluable disease (non-measurable lesions) outside irradiated field on computed tomography (CT)/magnetic resonance imaging (MRI)
Disease may be measurable (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) or non-measurable but must be present in at least one non-liver site, where presence is defined as 1.5 cm or greater and visualized on PET/CT with [18F]-fluorodeoxyglucose (FDG); patients with effusion only disease or disease only in the liver are not eligible for the study
At least one lesion measurable according to PET Response Criteria in Solid Tumors (PERCIST) v1.0: > 2 cm in diameter to avoid PET partial volume effects
At least one site of measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) that is seen on CT, magnetic resonance imaging (MRI), or FDG PET/CT
Disease may be measurable (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) or non-measurable but must be present in at least one non-liver site, 1.5 cm or greater and visualized on PET/CT with [18F]-fluorodeoxyglucose (FDG). Patients with effusion only disease or disease only in the liver are not eligible for the study.
Disease measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, a mass of greater than 1 cm in the long axis and/or other tumor response criteria from an MSKCC institutional review board (IRB)-approved clinical research protocol; NOTE: study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment
Disease measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or other tumor response criteria from an MSKCC Institutional Review Board (IRB)-approved clinical research protocol; NOTE: Study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment
Disease is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (1.1 or original version) or other tumor response criteria from an MSKCC Institutional Review Board (IRB)-approved clinical research protocol\r\n* This criterion does not apply to patients with myeloproliferative neoplasm; the presence of active myeloproliferative neoplasm will be determined by applicable disease-specific diagnostic criteria and patient assessment by the patient’s oncologist and trial investigators (eg, manifestations of active myeloproliferative neoplasm [MPN] such as splenomegaly, abnormal blood counts, etc)
Eligible adult patients currently meeting inclusion criteria and will be treated with an investigational or recently approved therapeutic agent at HCI; the patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; RECIST imaging must be current and have been obtained within 30 days prior to the baseline imaging session
Subjects must have measurable disease by CT or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; to comply with PET Response Criteria in Solid Tumors (PERCIST) criteria, subjects should have at least one lesion measuring at least 2 cm in the longest diameter
Presence of at least one measurable lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Subjects are required to have measurable disease that has progressed through prior therapy and that includes a non-hepatic lesion for imaging that is >= 1.5 cm, as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST)
Subjects must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease according to RECIST v.1.1 (or Choi criteria and/or EORTC metabolic response criteria for solid tumors, in the case of GIST); or
Additional Inclusion Requirements for expansion cohorts only a) Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (Version 1.1) and at least 1 nonsignificant risk, non-target lesion accessible for biopsy per the guidelines above (for TAK-580 + nivolumab and TAK-202 (plozalizumab) + nivolumab only).
Measurable disease according to Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST)
Recurrent or metastatic disease, documented by imaging (CT scan, MRI, X-ray) and/or physical examination. In phase II, measurable disease as per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 is mandated. In phase Ib, patients with or without measurable disease are eligible.